In a previous study, tumor-infiltrating lymphocytes (TIL) have been reported to be effective for advanced cancer patients in experimental and clinical research.1, 2 TIL recognize specific antigens expressed by autologous tumor cells. However, this specific antigenicity is too low to achieve a high degree of antigenicity in therapeutic use. In order to solve this problem, Sekine et al. developed a feasible method to obtain large numbers of activated or effective T lymphocytes.3, 4 Cultivation of peripheral blood lymphocytes with immobilized anti-CD3 monoclonal antibody and human recombinant interleukin-2 induces a rapid and massive proliferation of T lymphocytes and greatly augments their cytotoxic activity. Administration of these activated TILs demonstrates significant clinical activity in some patients with several type of cancer, making it a useful adoptive immunotherapy.
On the basis of these techniques, we developed the improved cultivation with autologous plasma of patients containing specific antibody for membrane antigens of natural killer (NK) cells. Briefly, peripheral blood lymphocytes are cultivated with immobilized anti-CD3 monoclonal antibody and human recombinant interleukin-2 following Sekine’s method, adding several matrix proteins such as fibronectin in plasma or immobilized monoclonal antibody such as CD161 for NK cells.5 This improved cultivation method is used not only to obtain the above described activated T lymphocytes, but also Hyper T cells and NK cells. Hyper T cells, the name coined by us, are unique and immature multipotent T cells with various capabilities. These cells decrease as we age. In particular, a significant decline in number is seen in age groups over 50 years. Hyper T cells have more widely specific antigenicity for antigens expressed by autologous tumor cells, high ability of proliferation and keep their activity for long periods in vivo.6 Therefore, expansion of Hyper T cells promises to be a suitable and important factor of adoptive immunotherapy against cancer. NK cells represent a unique subset of lymphocytes, distinct from T lymphocytes. They contribute essential immune systems to host anti-microbial and anti-tumor immunity against cancer or viral infection without the requirement for prior immune sensitization of the host.7 NK cells function as promising effectors for adoptive immunotherapy against cancer.
In the developed method for the cultivation of T lymphocytes, Hyper T cells, and NK cells, three cells are cultured simultaneously. Culturing each cell separately has been established by several methods. However, those methods of cultivation have many problems with respect to cost, complexity and safety, and use materials of animal or allogeneic human origin, such as human serum albumin. Therefore, it has been completely adopted in general medical treatment in spite of greatly effective possibility. Because of these reasons we developed a simple method of culturing these cells, in this case T lymphocytes, Hyper T cells, and NK cells simultaneously. Using only animal and human free materials for cultivation is important for an immunotherapy designed for patients with cancer. Each cell is shown to be effective in medical treatment for the cancer, but many problems are also ignored. For example, it is said that NK cell difficulty permeates the tumor tissue for the size. It is necessary for NK cell to attack a tumor tissue after making it small by the T lymphocytes and Hyper T lymphocytes. Such a strategy makes it more effective and a sensible immune therapy. The combination of these three immune cells act in cooperation synergistically to overcome the weakness of each individually.
The combination therapy with systemically administered T lymphocytes, Hyper T cells, and NK cells demonstrated significant clinical activity in some patients with cancer in clinical trials involving more than 100 cases. The mean expansion index of harvested T lymphocytes, Hyper T cells, and NK cells was about 2500 fold during a cultivation period for 14 days as shown in the figure. Side effects associated with this therapy were only observed in rare cases. This method can be of benefit to patients and is a promising immunotherapy. We expect that the described immunotherapy will play a central role of future therapies against certain human cancers, both alone and in combination with other therapies such as GcMAF or hyperthermia treatment.
Hyper T/NK cell therapy:
Purchase your Colostrum MAF here using PayPal or credit card.Heart Pharmacy website
Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.2016 Integrative Medical Therapies conference - Osaka, Japan
Dr Toshio Inui
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.Research paper
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)
Dr Toshio Inui
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT
Dr Toshio Inui
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.Research paper
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.